Tezepelumab only biologic to consistently reduce exacerbations in severe allergic asthma - Healio

LOUISVILLE, Ky. — Of approved biologics for severe, allergic asthma, tezepelumab was the lone 1 to consistently trim the annualized exacerbation complaint crossed diligent subgroups, according to a lit review.

These results were presented successful an oral abstract astatine the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

When evaluating the wide population, researchers recovered that tezepelumab (Tezspire; Amgen, AstraZeneca) showed the top AAER simplification compared with dupilumab (Dupixent; Regeneron, Sanofi) and omalizumab (Xolair; Genentech, Novartis). Source: Adobe Stock

“Patients with uncontrolled, terrible allergic asthma whitethorn beryllium prescribed biologic therapies to trim exacerbations and amended illness control,” Jonathan A. Bernstein, MD, FACAAI, prof of objective medicine successful the section of interior medicine, part of immunology/allergy conception astatine the University of Cincinnati, and colleagues wrote. “Randomized controlled trials of these therapies person differed successful design, with varying results wide and by baseline humor eosinophil count.”

In a lit review, Bernstein and colleagues identified signifier 3 randomized controlled trials connected assorted FDA-approved biologic therapies for patients with a confirmed allergy to perennial aeroallergens, according to the survey abstract.

Researchers included studies that evaluated annualized asthma exacerbation complaint (AAER) simplification with the biologic vs. placebo successful the wide colonisation and/or among patients with either a precocious oregon debased humor eosinophil number astatine baseline. They past utilized these information to comparison biologics crossed antithetic subgroups.

When evaluating the wide population, researchers recovered that tezepelumab (Tezspire; Amgen, AstraZeneca) showed the top AAER simplification compared with dupilumab (Dupixent; Regeneron, Sanofi) and omalizumab (Xolair; Genentech, Novartis). Specifically, researchers observed complaint ratios (RR) of 0.42 (95% CI, 0.33-53) with tezepelumab compared with 0.54 (95% CI, 0.4-0.74) for 300 mg dupilumab, 0.63 (95% CI, 0.46-0.87) for 200 mg dupilumab, and 0.75 (95% CI, 0.61-0.92) for omalizumab.

Tezepelumab besides conferred an AAER simplification among individuals with perennial allergy and humor eosinophil number little than 300 cells/L (RR = 0.55; 95% CI, 0.4-0.75); this simplification persisted careless of a humor eosinophil number past and was not recovered with mepolizumab (Nucala, GlaxoSmithKline), benralizumab (Fasenra, AstraZeneca) oregon omalizumab, according to the abstract.

For patients with humor eosinophil counts of 300 cells/L oregon greater, researchers recovered AAER reductions with each the biologics assessed, but with greater reductions for tezepelumab (RR = 0.31; 95% CI, 0.21-0.44) than with dupilumab (200 mg, RR = 0.43; 300 mg, RR = 0.38; 95% CI not reached for either), benralizumab (RR = 0.54; 95% CI, 0.39-0.74), mepolizumab (RR = 0.42; 95% CI, 0.28-0.61 and RR = 0.34; 95% CI, 0.22-0.51) and omalizumab (RR = 0.68; 95% CI, 0.52-0.89).

“The efficacy of biologics varies considerably wide and by humor eosinophil count,” Bernstein and colleagues wrote. “These differences tin pass supplier attraction decisions.”